ECM Therapeutics develops regenerative materials designed to support tissue repair. Based in Warrendale, Pennsylvania, the company brings extracellular matrix hydrogel and matrix-bound nanovesicle technologies from Stephen Badylak’s University of Pittsburgh research into product development. Its cofounders include Badylak and Katie Collins. [1]
The hydrogel platform can be formulated for injection, molding, coating or filling irregular spaces. Its pipeline includes an investigational fistula-repair treatment in Phase 1 and preclinical programs for gastrointestinal stricture and dermal filling. [2]
The company is evaluating ECMT-100 for anorectal fistulas in a first-in-human study. Separately, its ECMT-100 WMD wound-management product received FDA 510(k) clearance in June 2026. [3] [4]